To evaluate the use of proton-pump inhibitors (PPIs) for stress ulcer prophylaxis in critically ill adults.
DATA SOURCES:
Computerized biomedical literature search of MEDLINE (1966–June 2002) was conducted using the MeSH headings proton-pump inhibitor, ulcer, critical care, and acid. References of selected articles were reviewed. A manual search of critical care, surgery, trauma, gastrointestinal, and pharmacy journals was conducted to identify relevant abstracts.
DATA SYNTHESIS:
Traditional medications used for stress ulcer prophylaxis include antacids, histamine2 receptor antagonists (H2RAs), and sucralfate. Few studies have evaluated PPIs for stress ulcer prophylaxis. The majority of studies have demonstrated that enteral or intravenous administration of PPIs to critically ill patients elevates intragastric pH and consistently maintains pH ≥4.0. PPIs are safe and seem to be as efficacious as H2RAs or sucralfate for prevention of bleeding from stress-related mucosal damage (SRMD) and they may provide cost minimization. The small patient populations limit the results of comparative studies.
CONCLUSIONS:
Available data indicate that PPIs are safe and efficacious for elevating intragastric pH in critically ill patients. PPIs should be used only as an alternative to H2RAs or sucralfate since the superiority of PPIs over these agents for preventing SRMD-associated gastrointestinal bleeding has not been established. Additional comparative studies with adequate patient numbers and pharmacoeconomic analyses are needed before PPIs are considered the agents of choice for stress ulcer prophylaxis.
SmytheMAZarowitzBJ. Changing perspectives of stress gastritis prophylaxis. Ann Pharmacother1994;28: 1073–85.
2.
ASHP Therapeutic guidelines on stress ulcer prophylaxis.ASHP Commission on Therapeutics. Approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm1999;56: 347–79.
3.
MutlaGMMutlaAFactorP. GI complications in patients receiving mechanical ventilation. Chest2001;119: 1222–41.
4.
LucasCESuwagaCRiddleJRectorFRosenbergBWaltAJ. Natural history and surgical dilemma of stress gastric bleeding. Arch Surg1971;102: 266–73.
5.
Ben-MenachemTMcCarthyBDFogelRSchiffmanRMPatelRVZarowitzBJProphylaxis for stress-related gastrointestinal hemorrhage: A cost effectiveness analysis. Crit Care Med1996;24: 338–45.
6.
SchumanRBSchusterDPZuckermanGR. Prophylactic therapy for stress ulcer bleeding: A reappraisal. Ann Intern Med1987;106: 562–7.
7.
Van der VoortPHJVan der HulstRWMZandstraDFGeraedtsAAVan der EndeATytgatGN. Prevalence of Helicobacter pylori infection in stress-induced gastric mucosal injury. Intensive Care Med2001;27: 68–73.
8.
HalmUHalmFTheinDMohrFWMossnerJ. Helicobacter pylori infection: A risk factor for upper gastrointestinal bleeding after cardiac surgery. Crit Care Med2000;28: 110–3.
9.
CookDHeylandDGriffithLCookRMarshallJPagliarelloJ. Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Crit Care Med1999;27: 2812–7.
10.
CookDJFullerHDGuyattGHMarshallJCLeasaDHallRIRisk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med1994;330: 377–81.
11.
BrownRBKlarJTeresDLemeshowSSandsM. Prospective study of clinical bleeding in intensive care unit patients. Crit Care Med1988;16: 1171–6.
12.
ZarzaurBLKudskKACarterKPritchardFEFabianTCCroceMAStress ulceration requiring definitive surgery after severe trauma. Am Surg2001;67: 875–9.
13.
SchusterDPRowleyHFeinsteinSMcGueMKZuckermanGR. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med1984;76: 623–30.
14.
TrybaMCookD. Current guidelines on stress ulcer prophylaxis. Drugs1997;54: 581–96.
15.
MetzCALivingstonDHSmithJSLarsonGMWilsonTH. Impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding: A prospective, multicenter, double-blind, randomized study. Crit Care Med1993;21: 1844–9.
16.
MacLarenRJarvisCLFishDN. Use of enteral nutrition for stress ulcer prophylaxis. Ann Pharmacother2001;35: 1614–23.
17.
LacroixJInfante-RivardCJenicekMGauthierM. Prophylaxis of upper gastrointestinal bleeding in intensive care units: A meta-analysis. Crit Care Med1989;17: 862–9.
18.
TrybaM. Prophylaxis of stress ulcer bleeding: A meta-analysis. J Clin Gastroenterol1991;13(suppl 2):S44–55.
19.
CookDJWittLGCookRJGuyattGH. Stress ulcer prophylaxis in the critically ill: A meta analysis. Am J Med1991;91: 519–27.
20.
CookDJReeveBKScholesC. Histamine-2-receptor antagonists and antacids in the critically ill population: Stress ulceration versus nosocomial pneumonia. Infect Control Hosp Epidemiol1994;15: 437–42.
21.
CookDJReeveBKGuyattGHHeylandDKGriffithLEBuckinghamLStress ulcer prophylaxis in critically ill. Resolving discordant meta-analyses. JAMA1996;275: 308–14.
22.
TrybaM. Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: A meta-analysis on efficacy and pneumonia rate. Crit Care Med1991;19: 942–9.
23.
CookDJLaineLAGuyattGHRaffinTA. Nosocomial pneumonia and the role of gastric pH: A meta-analysis. Chest1991;100: 7–13.
24.
MessoriATrippoliSVaianiMGoriniMCorradoA. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: Meta-analysis of randomized controlled trials. BMJ2000;321: 1–7.
25.
CookDGuyattGMarshallJCLeasaDFullerHHallRA comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding patients requiring mechanical ventilation. N Engl J Med1998;338: 791–7.
26.
LamNPLePTCrawfordSYPatelS. National survey of stress ulcer prophylaxis. Crit Care Med1999;27: 98–103.
27.
MathotRAGeusWP. Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: Characterization of tolerance. Clin Pharmcol Ther1999;66: 140–51.
28.
LachmanLHowdenCW. Twenty-four-hour intragastric pH: Tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol2000;95: 57–61.
29.
SandvikAKBrennaEWaldumHL. Review article: The pharmacological inhibition of gastric acid secretion — Tolerance and rebound. Aliment Pharmacol Ther1997;11: 1013–8.
30.
TrofeJPetersonAM. The role of H2-receptor antagonists in the pathogenesis of nosocomial pneumonia in mechanically ventilated patients. Pharmacotherapy1998;18: 808–15.
31.
TrybaMCookDJ. Gastric alkalinization, pneumonia, and systemic infections: The controversy. Scand J Gastroenterol1995;210(Suppl):53–9.
32.
BaghaieAAMojtahedzadehMLevineRLFrommREJr.GuntupalliKKOpekunARJr.Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: Results of a prospective, randomized, crossover study. Crit Care Med1995;23: 687–91.
33.
IxkesMCKoopmanMGvan AckerBAWeberJAAriszL. Cimetidine improves GFR-estimation by the Cockcroft and Gault formula. Clin Nephrol1997;47: 229–36.
34.
PisegnaJR. Pharmacology of acid suppression in the hospital setting: Focus on proton pump inhibition. Crit Care Med2002;30(Suppl):S356–61.
35.
DiGiacintoJLOlsenKMBergmanKLHoieEB. Stability of suspension formulations of lansoprazole and omeprazole stored in amber-colored plastic oral syringes. Ann Pharmacother2000;34: 600–5.
36.
CohenHBaldwinSNMukherjiRRamosLDasguptaSDiGregorioRVA comparison of lansoprazole and sucralfate for the prophylaxis of stress-related mucosal damage in critically ill patients (abstract). Crit Care Med2000;28:A185.
37.
SharmaVK. Comparison of 24-hour gastric pH using four liquid formulations of lansoprazole and omeprazole. Am J Health Syst Pharm1999;56(23suppl 4):S18–21.
38.
SongJCQuerciaRAFanCTsikourisJWhiteCM. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension. Am J Health Syst Pharm2001;58: 689–94.
39.
SharmaVKPeytonBSpearsTRaufmanJPHowdenCW. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther2000;14: 887–92.
40.
DoanTTWangQGriffinJSLukasikNLO'DeaRFPanWJ. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am J Health Syst Pharm2001;58: 1512–9.
41.
PhillipsJOOlsenKMRebuckJARangnekerNJMiedemaBWMetzlerMH. A randomized, pharmacokinetic and pharmacodynamic, crossover study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol2001;96: 367–72.
42.
BalabanDHDuckworthCWPeuraDA. Nasogastric omeprazole: Effects on gastric pH in critically ill patients. Am J Gastroenterol1997;32: 79–83.
43.
LevyMJSeeligCBRobinsonNJRanneyJE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci1997;42: 1255–9.
44.
TaubelJJSharmaVKChiuYLLukasikNLPilmerBLPanWJ. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: Effects on 24-h gastric pH. Aliment Pharmacol Ther2001;15: 1807–17.
45.
KimbelKH. Suspension of licence for intravenous omeprazole in Germany (letter). Lancet1994;344:756.
46.
LaterrePFHorsmansY. Intravenous omeprazole in critically ill patients: A randomized, crossover study comparing 40 with 80 mg plus 8 mg/hour on intragastric pH. Crit Care Med2001;29: 1931–5.
47.
RobertsKWPitcherWDCryerB. Effect of lansoprazole suspension versus continuous intravenous ranitidine on gastric pH of mechanically ventilated intensive care unit patients (abstract). Crit Care Med2000;28:A185.
48.
MorrisJKarlstadtRBlatcherDFieldD. Intermittent intravenous pantoprazole rapidly achieves and maintains gastric pH ≥4.0 compared with continuous infusion H2-receptor antagonist in intensive care unit patients (abstract). Crit Care Med2001;29(Suppl):A147.
49.
OtaniYKitajimaMSugiyamaMWatanabeYAokiT. Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress. J Clin Gastroenterol1995;20(suppl 2):S22–6.
50.
PhillipsJOMetzlerMHPalmieriTLHuckfeldtREDahlNG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med1996;24: 1793–800.
51.
LaskyMRMetzlerMHPhillipsJO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma1998;44: 527–33.
52.
PhillipsJOMetzlerMHHuckfeldtREOlsenK. A multicenter, prospective, randomized clinical trial of continuous I.V. ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcer prophylaxis (abstract). Crit Care Med1998;26:A101.
